000756 新华制药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.5895.6849.84911.44110.826
总资产报酬率 ROA (%)0.9193.1855.4326.0005.271
投入资产回报率 ROIC (%)1.1143.8996.6937.4226.631

边际利润分析
销售毛利率 (%)18.20518.78524.11429.52427.154
营业利润率 (%)4.9134.1586.3126.5996.354
息税前利润/营业总收入 (%)5.5074.4956.4476.7786.715
净利润/营业总收入 (%)3.4363.4995.7496.2485.679

收益指标分析
经营活动净收益/利润总额(%)92.377101.55898.566106.994102.275
价值变动净收益/利润总额(%)0.2812.1631.8431.7991.773
营业外收支净额/利润总额(%)-0.337-1.412-0.134-0.356-1.045

偿债能力分析
流动比率 (X)1.7641.4351.3331.3331.094
速动比率 (X)1.2350.9660.8780.8050.711
资产负债率 (%)38.29640.60642.15442.36547.372
带息债务/全部投入资本 (%)25.97627.75828.88728.63335.112
股东权益/带息债务 (%)273.028249.553235.109237.510175.807
股东权益/负债合计 (%)154.036139.646131.285129.703105.390
利息保障倍数 (X)9.02011.38144.95633.57815.734

营运能力分析
应收账款周转天数 (天)36.69535.58233.33932.46634.062
存货周转天数 (天)57.53165.59272.44679.60873.754